Sone-220 Free May 2026

SONE-220 was evaluated in a medulloblastoblastoma mouse model, which exhibits aberrant Shh signaling. The compound was administered orally at a dose of 50 mg/kg twice daily for 14 days. SONE-220 significantly inhibited tumor growth, with a tumor growth inhibition (TGI) value of 75%. The compound also showed good pharmacokinetic properties, with a plasma half-life of 4 hours and a bioavailability of 80%.

: It might be the title of a creative work, such as a piece of music, a book chapter, or an art project. SONE-220

This model is designed for ceiling mounting and combines high-performance ventilation with integrated lighting. such as a piece of music